Switch theme
Sign up to access all valuation multiples
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
2009
305
LTM Revenue n/a
LTM EBITDA n/a
-$388M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bicycle Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Bicycle Therapeutics achieved revenue of $37.9M and an EBITDA of -$177M.
Bicycle Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bicycle Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $29.0M | $37.9M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$182M | -$177M | XXX | XXX | XXX |
| EBITDA Margin | -628% | -467% | XXX | XXX | XXX |
| Net Profit | -$121M | -$194M | XXX | XXX | XXX |
| Net Margin | -418% | -512% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Bicycle Therapeutics's stock price is EUR 6 (or $6).
Bicycle Therapeutics has current market cap of EUR 412M (or $442M), and EV of -EUR 361M (or -$388M).
See Bicycle Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$388M | $442M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Bicycle Therapeutics has market cap of $442M and EV of -$388M.
Bicycle Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Bicycle Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Bicycle Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$388M | XXX | XXX | XXX |
| EV/Revenue | -10.2x | XXX | XXX | XXX |
| EV/EBITDA | 2.2x | XXX | XXX | XXX |
| P/E | -2.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 2.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBicycle Therapeutics's NTM/LTM revenue growth is n/a
Bicycle Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.9M for the same period.
Over next 12 months, Bicycle Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Bicycle Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Bicycle Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 31% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -467% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -3% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 203% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 490% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 693% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bicycle Therapeutics acquired XXX companies to date.
Last acquisition by Bicycle Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Bicycle Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Bicycle Therapeutics founded? | Bicycle Therapeutics was founded in 2009. |
| Where is Bicycle Therapeutics headquartered? | Bicycle Therapeutics is headquartered in Germany. |
| How many employees does Bicycle Therapeutics have? | As of today, Bicycle Therapeutics has 305 employees. |
| Who is the CEO of Bicycle Therapeutics? | Bicycle Therapeutics's CEO is Dr. Kevin Lee, M.B.A.. |
| Is Bicycle Therapeutics publicy listed? | Yes, Bicycle Therapeutics is a public company listed on BER. |
| What is the stock symbol of Bicycle Therapeutics? | Bicycle Therapeutics trades under 50BA ticker. |
| When did Bicycle Therapeutics go public? | Bicycle Therapeutics went public in 2019. |
| Who are competitors of Bicycle Therapeutics? | Similar companies to Bicycle Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Bicycle Therapeutics? | Bicycle Therapeutics's current market cap is $442M |
| What is the current revenue growth of Bicycle Therapeutics? | Bicycle Therapeutics revenue growth between 2023 and 2024 was 31%. |
| Is Bicycle Therapeutics profitable? | Yes, Bicycle Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
